Drugs / Polyhexamethyl biguanide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02506257 | Nov 2015 → Apr 2016 | Acanthamoeba keratitis | SIFI SpA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyhexamethyl biguanide | “Polyhexamethyl biguanide (PHMB), a widely used topical treatment for Acanthamoeba keratitis (AK), is unlicensed with no formal safety assessment.” PMID 33239413 ↗ Nov 2020 |
| Known as | PHMB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02506257 ↗ |
| Route | Topical | “Polyhexamethyl biguanide (PHMB), a widely used topical treatment for Acanthamoeba keratitis (AK), is unlicensed with no formal safety assessment.” PMID 33239413 ↗ Nov 2020 |